#Germany #Frankfurt #gene therapy #Cell Therapy #Cellex

Cellex Symposium 2025: Insights into Cell and Gene Therapy

The Cellex Symposium took place on November 6, 2025, in Frankfurt/Main, Germany, under the theme 'The Evolving Field of Cell and Gene Therapy.' This prestigious event gathered over 100 participants from Europe, Asia, and North America, including top scientists, industry leaders, clinical practitioners, investors, and regulatory authorities.

Dr. Armin Ehninger, Chief Scientific and Strategic Officer at Cellex Cell Professionals GmbH, opened the symposium by emphasizing the company’s commitment to enhancing the progress in cell and gene therapy. He pointed out that scientific excellence, collaborative exchange, reliable manufacturing, and the highest quality standards are crucial for achieving significant advances in advanced therapies.

Innovating in Immunotherapy: Key Discussions

The inaugural session highlighted innovation, funding, and next-generation platforms in immunotherapy. Dr. Karl Nägler from Sofinnova Partners provided an insightful overview of the venture capital landscape related to gene and cell therapies. He delved into the opportunities and challenges that investors face in this evolving sector. Meanwhile, Kenneth Locke shared promising developments in utilizing cell-derived nanoparticles to overcome barriers in T-cell activation and proliferation.

Dr. Jiri Eitler from the Technical University of Dresden discussed novel accessibility strategies for CAR-NK therapies in oncology, while Dr. Jessica Hartmann from the Paul Ehrlich Institute emphasized that sustained innovation relies on robust frameworks to translate scientific advances into scalable and high-quality manufacturing solutions.

Navigating Clinical Innovations for Patient Impact

As part of the symposium, the 'Clinical Navigation' session focused on therapeutic frontiers and digital transformation within clinical settings. Prof. Dimitrios Mougiakakos from Magdeburg University Hospital and Prof. Ralf Gold from Ruhr University Bochum presented pioneering work on CAR-T therapies for autoimmune and neuromuscular diseases. Prof. Christof Scheid shared early experiences relating to outpatient CAR-T therapy, showcasing its emerging reality in clinical practice.

Dr. Moritz Middeke from Cancilico demonstrated the integration of artificial intelligence in cancer diagnosis and treatment, highlighting how AI-driven decision-making can expedite precision medicine.

In a roundtable discussion titled 'Cell and Gene Therapy 2035: Transformative Changes in Science, Systems, and Scale,' industry leaders and academics gathered to discuss broadening access to cell and gene therapies and how manufacturing processes might evolve in the future.

Manufacturing: A Strategic Enabler of Innovation

The closing session of the symposium re-centered discussions on manufacturing strategies. Gabriela Valentová from Johnson & Johnson opened with reflections on how timely and relevant data can optimize manufacturing outcomes. Tom Brenner from Stefan-Morsch-Stiftung addressed challenges in donor material acquisition and integration within registries.

Dr. Gunther Busam from Orchard Therapeutics delved into process design for scalability and supply efficiency, while Prof. Michael Hudecek from Würzburg University Hospital presented innovations in CAR-T cell manufacturing.

The central message emphasized that CMC capabilities should not just be viewed as operational necessities but as strategic enablers. Cellex's integrated approach to process design, manufacturing analysis, and quality management illustrates how solid production infrastructures support both scientific advancement and clinical translation in gene and cell therapies.

Collaboration and Diversity at the Forefront

Beyond its scientific agenda, the symposium served as a platform for interdisciplinary collaboration. Attendees, including researchers, clinicians, and industry representatives, debated ways to enhance therapy accessibility and harmonize standards while integrating data-driven quality control in cell and gene therapies.

Prof. Gerhard Ehninger, founder and CEO of Cellex Cell Professionals GmbH, stated, 'The success of Cellex Symposium 2025 reinforces our belief that progress in gene and cell therapies requires both scientific excellence and collaborative input from numerous bright minds.' Cellex is proud to connect diverse sectors in this global effort.

About Cellex Cell Professionals GmbH

Cellex is a leading full-service CDMO specializing in cell and gene therapies (CGT). With state-of-the-art facilities in Cologne, Germany, Cellex has over ten years of proven experience in manufacturing autologous and allogeneic cell therapies according to GMP standards. The company collaborates with major pharmaceutical and biotechnology firms, supporting clinical and commercial manufacturing processes along with providing customized starting materials for research, clinical, and commercial studies.

To learn more, visit www.cellex.me/en. For media inquiries, contact us via email or phone.